181 related articles for article (PubMed ID: 38474414)
1. Unique Binding Sites of Uricosuric Agent Dotinurad for Selective Inhibition of Renal Uric Acid Reabsorptive Transporter URAT1.
Fujita K; Isozumi N; Zhu Q; Matsubayashi M; Taniguchi T; Arakawa H; Shirasaka Y; Mori E; Tamai I
J Pharmacol Exp Ther; 2024 Jun; 390(1):99-107. PubMed ID: 38670801
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical and in situ hybridization study of urate transporters GLUT9/URATv1, ABCG2, and URAT1 in the murine brain.
Tomioka NH; Tamura Y; Takada T; Shibata S; Suzuki H; Uchida S; Hosoyamada M
Fluids Barriers CNS; 2016 Dec; 13(1):22. PubMed ID: 27955673
[TBL] [Abstract][Full Text] [Related]
3. Dotinurad: a novel selective urate reabsorption inhibitor for the treatment of hyperuricemia and gout.
Ishikawa T; Takahashi T; Taniguchi T; Hosoya T
Expert Opin Pharmacother; 2021 Aug; 22(11):1397-1406. PubMed ID: 33926357
[TBL] [Abstract][Full Text] [Related]
4. A Possible Therapeutic Application of the Selective Inhibitor of Urate Transporter 1, Dotinurad, for Metabolic Syndrome, Chronic Kidney Disease, and Cardiovascular Disease.
Yanai H; Adachi H; Hakoshima M; Iida S; Katsuyama H
Cells; 2024 Mar; 13(5):. PubMed ID: 38474414
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
[TBL] [Abstract][Full Text] [Related]
6. Urate Transporter 1 Can Be a Therapeutic Target Molecule for Chronic Kidney Disease and Diabetic Kidney Disease: A Retrospective Longitudinal Study.
Yanai H; Katsuyama H; Hakoshima M; Adachi H
Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831103
[TBL] [Abstract][Full Text] [Related]
7. Dotinurad: a novel selective urate reabsorption inhibitor as a future therapeutic option for hyperuricemia.
Kuriyama S
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):1-5. PubMed ID: 31754883
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, in hyperuricemic patients with type 2 diabetic kidney disease: Protocol for a single-arm, open-label, prospective, exploratory study.
Osonoi T; Saito M; Hosoya M; Douguchi S; Ofuchi K; Katoh M
Front Endocrinol (Lausanne); 2022; 13():1042061. PubMed ID: 36714585
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study.
Hosoya T; Sano T; Sasaki T; Fushimi M; Ohashi T
Clin Exp Nephrol; 2020 Mar; 24(Suppl 1):53-61. PubMed ID: 31792640
[TBL] [Abstract][Full Text] [Related]
10. Hyperuricemia is associated with heart failure readmission in patients with heart failure and preserved ejection fraction-an observational study in Chinese.
Liu X; Huang G; You Y; Zhang Y; Wang T; Zhu Y; He Y; Li J; Zhang Z; Xu J
Nutr Metab Cardiovasc Dis; 2024 Feb; 34(2):521-528. PubMed ID: 38161130
[TBL] [Abstract][Full Text] [Related]
11. Febuxostat dose requirement according to renal function in patients who achieve target serum urate levels: A retrospective cohort study.
Kim YE; Ahn SM; Oh JS; Kim YG; Lee CK; Yoo B; Hong S
Joint Bone Spine; 2024 Mar; 91(2):105668. PubMed ID: 38036062
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy and Safety of Dotinurad on Uric Acid and Renal Function in Patients with Hyperuricemia and Advanced Chronic Kidney Disease: A Single Center, Retrospective Analysis.
Yanai K; Hirai K; Kaneko S; Mutsuyoshi Y; Kitano T; Miyazawa H; Ito K; Ueda Y; Ookawara S; Morishita Y
Drug Des Devel Ther; 2023; 17():3233-3248. PubMed ID: 37941891
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of dotinurad in patients with severe renal dysfunction.
Kurihara O; Yamada T; Kato K; Miyauchi Y
Clin Exp Nephrol; 2024 Mar; 28(3):208-216. PubMed ID: 37864678
[TBL] [Abstract][Full Text] [Related]
14. Hyperuricemia and Its Association With the Severity and Complications of Congestive Heart Failure: A Systematic Review.
Sn VP; Jaramillo AP; Yasir M; Hussein S; Singareddy S; Iyer N; Nath TS
Cureus; 2023 Sep; 15(9):e45246. PubMed ID: 37842413
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
